Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

この研究はインパクトが大きい可能性があると判断されました。 OEのAIによるハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文の影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することができ、読者は将来の診療を形成する可能性が最も高い論文に焦点を当てることができます。

研究概要

Of the 9433 patients participating in the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial, 7763 were randomized to receive azithromycin plus standard care (n=2582), or standard care alone (n=5181; 837 eventually crossed over to receive azithromycin or tocilizumab but were still included in the analysis). The primary outcome of interest was all-cause mortality at 28 days. Secondary outcomes of interest included time to discharge alive, incidence of discharge within 28 days, and the incidence of invasive mechanical ventilation or death. Additional outcomes of interest included the incidence of ventilation, incidence of non-invasive ventilation, the incidence of invasive mechanical ventilation, the proportion of patients with successful cessation of invasive mechanical ventilation, and the incidence of hemodialysis or filtration use. All outcomes were assessed at 28 days follow up. Results revealed no statistical significant differences between groups in the incidence of all-cause mortality at 28 days (p=0.50). This result was consistent in all subgroups, including age (i.e., ≤70, 70-80, ≥80), sex, ethnicity (i.e., white; black, asian, and minority ethnic), days since symptoms onset (i.e., ≤7; >7), respiratory support at randomization, and use of corticosteroids (p>0.05 for all). The median time to discharge alive was 10 days in the azithromycin group, and 11 days in the control group. There were no statistical significant differences between groups in all secondary and additional outcomes at 28 days follow-up (p>0.05 for all).